Want to see GRFS full AI Analyst Report?
GRFS Stock Chart & Stats
$8.78
-$0.21(-2.68%)
At close: 4:00 PM EST
$8.78
-$0.21(-2.68%)
Day’s Range― - ―
52-Week Range$6.96 - $11.14
Previous CloseN/A
Volume119.87K
Average Volume (3M)657.50K
Market Cap
$6.19B
Enterprise Value$15.09B
Total Cash (Recent Filing)$702.73M
Total Debt (Recent Filing)$9.68B
Price to Earnings (P/E)14.6
Beta0.88
Next Earnings
Jul 23, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend Yield1.56%
Share Statistics
EPS (TTM)0.61
Shares Outstanding261,425,100
10 Day Avg. Volume760,302
30 Day Avg. Volume657,501
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.03
Price to Sales (P/S)0.75
P/FCF Ratio7.21
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit5.38
Enterprise Value/Ebitda9.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.96
Revenue Forecast (FY)$8.88B
Bulls Say, Bears Say
Bulls Say
Vertical Plasma Sourcing Ramp (Egypt)Securing EMA-approved Egyptian plasma at scale materially strengthens Grifols’ raw-material base and reduces reliance on U.S. donors. A planned ~2.5x ex‑U.S. volume increase by 2029 should lower cost-per-liter, support steady production capacity, and sustainably improve biopharma margins over several years.
Margin Recovery And OpEx DisciplineDemonstrated OpEx cuts and a clear management target for higher adjusted-EBITDA margins indicate structurally improved cost control and margin resilience. If sustained, this elevates cash generation potential across cycles and provides buffer versus pricing or mix headwinds in plasma-derived therapies.
Refinancing And Extended LiquidityExtending maturities and increasing committed revolver capacity meaningfully reduces short-term refinancing risk and lowers cash interest exposure. This improved debt profile creates durable financial flexibility to fund plasma ramp, R&D and targeted capex while pursuing deleveraging over the medium term.
Bears Say
Elevated LeverageSustained high leverage constrains strategic optionality: it limits ability to pursue large M&A or aggressive share returns, increases sensitivity to interest-rate moves, and requires continued strong cash generation to hit deleveraging targets. Even with upgrades, balance-sheet risk remains a structural constraint.
Weak Revenue Momentum And Mix PressuresStagnant-to-declining revenue alongside mix headwinds (albumin weakness in China and specialty declines) undermines the quality of earnings. Without consistent top-line growth, margin gains risk proving cyclical and limit sustainable profit expansion over the medium term.
Cash-conversion And Working-capital FrictionWeak cash conversion versus operating profit and negative recent free-cash-flow growth indicate structural working-capital or conversion issues. This reduces true liquidity despite accounting profitability and complicates rapid deleveraging or reinvestment absent improved conversion or tighter inventory and receivables management.
Grifols SA News
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $6.96 and its highest was $11.14 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $6.19B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Jul 23, 2026 which is in 12 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on May 07, 2026. The company reported $0.126 earnings per share for the quarter, missing the consensus estimate of $0.161 by -$0.035.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.094 which represents an annual dividend yield of 1.56%. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.26.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.126 in its last earnings report, missing expectations of $0.161. Following the earnings report the stock price went down -4.171%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GRFS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.44%
12-Months-Change
Fundamentals
Return on Equity
7.88%
Trailing 12-Months
Asset Growth
2.09%
Trailing 12-Months
Company Description
Grifols SA
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
GRFS Company Deck
GRFS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive operational and financial picture: solid revenue growth, strong Biopharma and IG momentum, margin resilience, disciplined OpEx reductions, meaningful balance-sheet and liquidity improvements, and a strategically significant ramp in Egyptian plasma sourcing that supports long-term margin expansion. Near-term headwinds—most notably albumin weakness in China, a decline in Alpha‑1 & specialty proteins (driven in part by prior-year inventory effects and access frictions), reported Diagnostics revenue impact from the Quidel Ortho JV dissolution, seasonally negative free cash flow in Q1 and FX translation pressure—were acknowledged as largely temporary or manageable and offset by active mitigation plans (pricing/market access initiatives, center optimization, platform launches, and compensation from the JV dissolution). Overall, positives in execution, capital structure and strategic positioning materially outweigh the temporary operational and market challenges highlighted by management.View all GRFS earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.57% Mutual Funds
0.23% Other Institutional Investors
89.74% Public Companies and
Individual Investors